financetom
Business
financetom
/
Business
/
Boeing plans to launch effort to raise over $15 billion in capital as early as Monday, source says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boeing plans to launch effort to raise over $15 billion in capital as early as Monday, source says
Nov 3, 2024 12:13 PM

(Reuters) - Boeing ( BA ) is set to launch as early as Monday its plan to raise more than $15 billion in capital, a source briefed on the matter told Reuters.

Reuters first reported on Oct. 16 that the planemaker was closing in on a plan to raise around $15 billion with common shares and a mandatory convertible bond as it sought to bolster finances worsened by a crippling ongoing strike.

The new capital is set to come from a mix of the sale of stock and convertible preferred shares, the source added, saying the total amount raised could rise based on demand.

Boeing ( BA ) declined to comment on Sunday.

Bloomberg News reported the expected timing of Monday's capital raise earlier.

Last week, machinists voted nearly two to one to reject Boeing's ( BA ) latest offer seeking to end the strike that has halted 737 MAX production.

The company said earlier this month in regulatory filings that it could raise as much as $25 billion in stock and debt with its investment-grade credit rating at risk.

The aerospace giant has been dealing with increased regulatory scrutiny, production curbs and a loss of confidence from customers since a door panel blew off a 737 MAX plane in midair in early January.

Boeing ( BA ) has been burning through cash all year and last week announced a new $6 billion quarterly loss. Earlier this month, Boeing ( BA ) said it had secured a $10 billion credit agreement with major lenders: Bank of America, Citibank, Goldman Sachs and JPMorgan.

   Boeing said earlier this month it would cut 17,000 jobs - 10% of its global workforce - and delay first deliveries of its 777X jet by a year.

The top three credit rating agencies - S&P, Moody's and Fitch - have said they will cut Boeing's ( BA ) ratings to junk if it raised new debt without retiring some $11 billion of debt maturing through Feb. 1, 2026.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CBB Bancorp Q3 profit rises, deposits up 9%
CBB Bancorp Q3 profit rises, deposits up 9%
Oct 24, 2025
Overview * CBB Bancorp ( CBBI ) Q3 net income rises to $4.5 mln, EPS at $0.43 * Net interest margin for Q3 improves to 3.49% from 3.46% in prior quarter * Company's deposits increase by $141.4 mln, reflecting strong inflows Outlook * CBB Bancorp ( CBBI ) focuses on sustaining prudent risk management and enhancing operational efficiency Result Drivers...
Sector Update: Consumer Stocks Advance Pre-Bell Friday
Sector Update: Consumer Stocks Advance Pre-Bell Friday
Oct 24, 2025
09:14 AM EDT, 10/24/2025 (MT Newswires) -- Consumer stocks were advancing pre-bell Friday, with the Consumer Staples Select Sector SPDR Fund ( XLP ) up 0.4% and Consumer Discretionary Select Sector SPDR Fund ( XLY ) up 0.3%. Procter & Gamble ( PG ) shares were up more than 3% after the company posted higher fiscal Q1 core earnings and...
SEALSQ Receives Uplisting Approval of Shares to Nasdaq Global Select Market
SEALSQ Receives Uplisting Approval of Shares to Nasdaq Global Select Market
Oct 24, 2025
09:13 AM EDT, 10/24/2025 (MT Newswires) -- SEALSQ ( LAES ) said Friday that its shares have been approved for trading on the Nasdaq Global Select Market, uplisting from the Nasdaq Capital Market, effective Oct. 27. The company also said it recently surpassed $1 billion in market capitalization. SEALSQ ( LAES ) shares were up 5.2% in recent Friday premarket...
Lilly to Acquire Adverum Biotechnologies
Lilly to Acquire Adverum Biotechnologies
Oct 24, 2025
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose  Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases  INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved